ERBB2 and breast cancer: Amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) (HER2/neu, ERBB2) oncogene occur in 15 to 25% of invasive BC [1,2] and define a clinically important subgroup (HER2+).